MRKR News and Press, Marker Therapeutics Inc. From 03/05/25

2025-03-05 16:30:02 ET Jefferies analyst issues BUY recommendation for MRKR on March 5, 2025 05:24PM ET. MRKR was trading at $2.049 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 4 - Buy, 1 - Hold recomm...

2025-03-05 13:30:03 ET Barclays analyst issues EQUAL-WEIGHT recommendation for MRKR on March 5, 2025 05:24PM ET. MRKR was trading at $2.049 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 1 - Buy recommen...

2025-03-05 13:15:03 ET Oppenheimer analyst issues OUTPERFORM recommendation for MRKR on March 5, 2025 05:24PM ET. MRKR was trading at $2.049 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 1 - Buy recomme...

2025-03-05 13:15:03 ET Canaccord Genuity analyst issues BUY recommendation for MRKR on March 5, 2025 05:24PM ET. MRKR was trading at $2.049 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 1 - Buy recommen...

HOUSTON, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that J...

2025-01-23 12:55:36 ET More on Illumina, Pacific Biosciences of California, etc. Illumina, Inc. (ILMN) 43rd Annual JPMorgan Healthcare Conference - (Transcript) 10x Genomics: Struggling Amid Operational Challenges Illumina And Grail In 2025? Grounds For Optimism, If ...